Researchers Find New Potential Biomarkers Associated With Idiopathic Pulmonary Fibrosis Progression

Liposomes Loaded With Anti-fibrotic Drugs Offer Promising Idiopathic Pulmonary Fibrosis Treatment Approach

In a recent study entitled “Efficient Delivery to Human Lung Fibroblasts (WI-38) of Pirfenidone Incorporated into Liposomes Modified with Truncated Basic Fibroblast Growth Factor and Its Inhibitory Effect on Collagen Synthesis in Idiopathic Pulmonary Fibrosis,” researchers highlighted a promising, novel treatment for idiopathic pulmonary fibrosis that…

Aeolus’ Idiopathic Pulmonary Fibrosis Compound Gets Orphan Drug Status

Orphan Drug Status was recently granted to an experimental compound, AEOL 10150, under development by Aeolus Pharmaceuticals to address the need for novel treatments for idiopathic pulmonary fibrosis. AEOL 10150 is a broad-spectrum catalytic antioxidant thought to neutralize reactive nitrogen and oxygen species and, consequently, reduce inflammation, oxidative stress and subsequent…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums